Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BETRF NASDAQ:ESLA NYSEMKT:IGC NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.06-3.7%$0.07$0.05▼$0.13$9.22M1.399,892 shs4,590 shsESLAEstrella Immunopharma$1.06+2.9%$0.92$0.63▼$1.78$38.19M0.3723,818 shs22,543 shsIGCIGC Pharma$0.42+27.3%$0.37$0.25▼$0.48$39.38M1.08913,992 shs214,616 shsTELOTelomir Pharmaceuticals$1.26-7.4%$1.54$1.12▼$8.40$43.90M-0.734.62 million shs1.12 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%-7.33%-3.65%-8.03%-39.30%ESLAEstrella Immunopharma+1.92%-1.85%+20.18%+4.95%+6.00%IGCIGC Pharma-0.95%-9.39%+16.90%+30.91%+12.77%TELOTelomir Pharmaceuticals-7.35%+6.78%-20.25%-37.00%-78.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.06-3.7%$0.07$0.05▼$0.13$9.22M1.399,892 shs4,590 shsESLAEstrella Immunopharma$1.06+2.9%$0.92$0.63▼$1.78$38.19M0.3723,818 shs22,543 shsIGCIGC Pharma$0.42+27.3%$0.37$0.25▼$0.48$39.38M1.08913,992 shs214,616 shsTELOTelomir Pharmaceuticals$1.26-7.4%$1.54$1.12▼$8.40$43.90M-0.734.62 million shs1.12 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%-7.33%-3.65%-8.03%-39.30%ESLAEstrella Immunopharma+1.92%-1.85%+20.18%+4.95%+6.00%IGCIGC Pharma-0.95%-9.39%+16.90%+30.91%+12.77%TELOTelomir Pharmaceuticals-7.35%+6.78%-20.25%-37.00%-78.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife Pharma 0.00N/AN/AN/AESLAEstrella Immunopharma 3.00Buy$16.001,409.43% UpsideIGCIGC Pharma 3.00Buy$3.88833.73% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,090.48% UpsideCurrent Analyst Ratings BreakdownLatest BETRF, ESLA, TELO, and IGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.04) per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AN/AIGCIGC Pharma$1.33M28.40N/AN/A$0.08 per share5.19TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$2.55M-$0.01N/A∞N/AN/AN/A-609.07%9/23/2025 (Estimated)ESLAEstrella ImmunopharmaN/A-$0.26N/A∞N/AN/A-1,132.38%-358.54%9/26/2025 (Estimated)IGCIGC Pharma-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest BETRF, ESLA, TELO, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.040.04ESLAEstrella ImmunopharmaN/A0.160.16IGCIGC Pharma0.021.150.98TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%ESLAEstrella Immunopharma0.35%IGCIGC Pharma3.87%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%ESLAEstrella Immunopharma55.10%IGCIGC Pharma23.66%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7151.84 million99.05 millionNot OptionableESLAEstrella ImmunopharmaN/A37.07 million16.64 millionNot OptionableIGCIGC Pharma6190.81 million54.60 millionN/ATELOTelomir Pharmaceuticals132.28 millionN/AN/ABETRF, ESLA, TELO, and IGC HeadlinesRecent News About These CompaniesTELO Releases Cancer Suppressing ResultsSeptember 9 at 7:53 PM | msn.comTelomir Pharmaceuticals announces preclinical cancer data on Telomir-1September 9 at 7:53 PM | msn.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor ...September 9 at 9:51 AM | charlotteobserver.comCTelomir Pharmaceuticals Unveils Promising Preclinical Cancer DataSeptember 9 at 8:11 AM | tipranks.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapySeptember 9 at 8:00 AM | accessnewswire.comATelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest UpdateSeptember 8 at 3:49 AM | americanbankingnews.comTelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4, 2025 | tipranks.comHead to Head Survey: Telomir Pharmaceuticals (NASDAQ:TELO) & 4D Molecular Therapeutics (NASDAQ:FDMT)September 2, 2025 | americanbankingnews.comTelomir stock soars after drug candidate shows promising epigenetic effectsAugust 28, 2025 | za.investing.comTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...August 28, 2025 | kansascity.comKTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesAugust 28, 2025 | accessnewswire.comATELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir-1 inhibits key histone demethylase enzymes in vitroAugust 12, 2025 | bioworld.comBTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...August 8, 2025 | kansascity.comKTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionAugust 7, 2025 | accessnewswire.comATelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comTELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sJuly 24, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTesla's Breakout: Why This Rally Looks Far From OverBy Sam Quirke | August 20, 2025Tesla’s Pennant Just Snapped: Here’s What It Means for the StockBy Sam Quirke | August 14, 2025Tesla Just Had Its Best Day in 2 Months—Here’s What It MeansBy Sam Quirke | August 26, 2025Tesla Bulls Need to Tread Very Carefully Right NowBy Sam Quirke | September 3, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025BETRF, ESLA, TELO, and IGC Company DescriptionsBetterLife Pharma OTCMKTS:BETRF$0.06 0.00 (-3.65%) As of 09/9/2025 02:11 PM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Estrella Immunopharma NASDAQ:ESLA$1.06 +0.03 (+2.88%) Closing price 09/10/2025 03:58 PM EasternExtended Trading$1.03 -0.03 (-2.36%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.IGC Pharma NYSEMKT:IGC$0.42 +0.09 (+27.26%) Closing price 09/10/2025 03:59 PM EasternExtended Trading$0.41 -0.01 (-2.17%) As of 06:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Telomir Pharmaceuticals NASDAQ:TELO$1.26 -0.10 (-7.35%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.79%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
